QiuHang Health Completes Pre-A Funding Round to Advance Standardized POCT Smart Testing Labs

VCBeat has learned that Qiuhang (Zhejiang) Health Management Co., Ltd. (hereinafter referred to as “Qiuhang Health”) recently announced the completion of its Pre-A round of financing, with investors including Beijing Fanzhi Medical Technology Co., Ltd. and the “Fanzhi Cloud Chain” ecosystem enterprise platform. The funds from this round will be primarily used forConstruction, R&D, and Project Operation of Smart POCT Laboratories.

Qiuhang Health is committed to building for the primary healthcare sectorStandardized POCT Smart Laboratory Testing Service Platform, equipped with a range of leading domestic rapid diagnostic intelligent devices and consumables for import substitution, by establishing for primary healthcare institutions“Big Data + Primary Healthcare + Rapid Testing Services”, launch a new primary healthcare service platform, optimize the skills of primary care physicians, enhance their initial diagnostic capabilities, and support the development of China’s primary healthcare system.

With socioeconomic development and the deepening of healthcare reform, China’s primary healthcare sector has grown rapidly, with village clinics playing a vital role. According to statistics from the National Health Commission, by the end of 2021, there were 978,000 primary healthcare institutions nationwide, including 599,000 village clinics, which handled 1.34 billion patient visits annually.^【1】. The development of village-level medical institutions is bound to enter a new phase of development,Standardization, Enhanced Health Management, and Improved Medical Services: The Future Development Themes for Village Clinics

From health-focused poverty alleviation to health revitalization, the primary goal is to enhance the efficiency of prevention, diagnosis, and treatment. Among these, prevention and early detection are paramount; both rely heavily on timely diagnosis. The simplicity, speed, convenience, and connectivity offered by Point-of-Care Testing (POCT) perfectly meet this need. In contrast, traditional centralized laboratories face significant implementation challenges in primary healthcare institutions, where costs are disproportionate to utilization rates and staffing capabilities fall short.Future miniaturized smart POCT laboratories are better suited for primary healthcare settings.

POCT (Point of Care Testing) refers to point-of-care testing. It is a product category distinct from large-scale laboratory testing systems. While large-scale laboratory products require high-throughput, assembly-line, batch processing, and standardized operations, POCT products emphasize speed, convenience, and simple, flexible operation. Analysis can be performed directly at the sampling site, eliminating the complex processing procedures required for specimens in laboratory testing, thereby enabling rapid acquisition of test results.

The unmet needs at the primary care level represent a vast market opportunity in China’s current healthcare landscape. Qiuhang Health focuses on building standardized, smart POCT (Point-of-Care Testing) laboratories for primary care institutions, aligning with policy directives and future development trends, thereby offering significant growth potential.

QiuHang Health is composed of senior executives from listed companies in the testing industry, renowned experts in the medical field, and well-known software engineers. By leveraging digital technologies to build a smart community healthcare service team, it meets the health management needs of primary care patients, thereby achieving precise decentralization of medical services.

Leveraging cutting-edge technologies such as IoT-based big data cloud warehousing for POCT rapid testing devices, artificial intelligence, and biofeedback, Qiuhang Health has developed a standardized smart POCT laboratory service platform. The platform is equipped with a variety of leading domestically produced intelligent rapid testing devices and consumables that serve as import substitutes, enabling the performance of over 30 routine test items with reports available within 20 minutes. Additionally, its smart chronic disease management “cloud” system will, in the future, integrate electronic health records with daily monitoring data from wearable devices onto the cloud for comprehensive analysis, facilitating timely detection, prompt treatment, and standardized management to reduce complications.

QiuHang Health is actively promoting the construction of standardized primary-care laboratories and establishing integrated diagnosis-and-treatment command service stations. Currently,Three hundred primary healthcare sites have been established, enhancing the initial diagnostic capabilities of primary care physicians, supporting national primary healthcare infrastructure development, and bridging the last mile in healthcare delivery.

Among these initiatives, the POCT laboratory has supported the Ningbo government in implementing the “Health E-Station” project, upgrading community service stations and empowering community healthcare management through a new internet-based medical model featuring a “health management platform + intelligent testing devices.” This approach has gained widespread recognition. To date, POCT chronic disease testing laboratories have been successfully deployed in 210 primary care service stations across the Ningbo region.

As a company focused on the medical technology sector, Beijing Fanzhi Medical Technology Co., Ltd.’s investment in Qiuhang Health fully demonstrates its recognition of the latter’s development potential and prospects in standardized POCT smart laboratories. At the same time, Fanzhi Medical directly empowers Qiuhang Health with its independently developed rapid diagnostic instruments and diagnostic products, significantly boosting its efficiency in the construction of primary healthcare systems. Fanzhi Medical believes that, leveraging its professional team, extensive industry experience, and strong channel expansion capabilities, Qiuhang Health will achieve greater breakthroughs and accomplishments in the field of primary healthcare, enabling more ordinary people to enjoy more convenient diagnosis and treatment services, and contributing more strength to the construction of the national basic healthcare system.

It is reported that the funds raised in this round will be primarily allocated to the construction of smart POCT (Point-of-Care Testing) laboratories, technological research and development, and project operations. Qiuhang Health will vigorously advance the deployment of standardized smart laboratory sites to enhance service quality and user experience. The completion of this financing round marks a new milestone in the company’s development. With full confidence in the future, Qiuhang Health is committed to continuous innovation and progress, aiming to provide grassroots populations with more convenient and precise POCT rapid diagnostic services, thereby establishing itself as China’s leading intelligent diagnosis and treatment brand for primary healthcare.

Beijing Fanzhi Medical Technology Co., Ltd. is a globally operating biopharmaceutical enterprise founded by senior overseas-returned scientists, researchers from the Chinese Academy of Sciences, and clinical experts. The company provides integrated product and service solutions encompassing instruments, chips, diagnostic reagents, and internet-based remote diagnosis and treatment. It aims to facilitate the integration of advanced rapid disease diagnostic technologies into primary healthcare systems, enabling the general public to access more convenient diagnostic and therapeutic services, while establishing an internationally advanced brand for the rapid diagnosis and treatment of major diseases. Committed to independent research and development, the company is one of the few specialized, refined, distinctive, and innovative (“Little Giant”) enterprises in China’s rapid disease detection sector with in-house capabilities in four core underlying technologies: nucleic acids, chips, mechanics, and software.

The company possesses robust independent R&D capabilities, having successively overcome high-barrier import substitution challenges in nucleic acid testing systems, achieved localization of core key raw materials, and resolved issues related to integrated rapid detection chips. It has established four advanced underlying technology development platforms in the field of nucleic acid testing, enhancing its capacity for product iteration and diversification. Through steadfast commitment to and innovation in foundational technologies, the company has not only realized import substitution but also gained the potential to compete internationally. It currently holds over 150 patents and related intellectual property rights, has completed seven rounds of financing, and its products have entered more than 30 countries worldwide, with its technological prowess reaching an internationally advanced level. By leveraging independent R&D, core underlying technologies, and products to deeply empower nearly 20 upstream and downstream enterprises, the company has initially built the “Fanzhi Cloud Chain” ecosystem cluster, fostering collaborative development among these entities. This has essentially enabled control over underlying technologies, supply chains, and distribution channels, equipping the company with the strategic capability to compete long-term with top-tier international brands during the import substitution process while maintaining unique innovative competitive advantages.

References:

^【1】Source: National Health Commission Website, "Statistical Bulletin on the Development of China's Health and Health Services in 2021"